These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28625555)

  • 21. Neoadjuvant pembrolizumab in bladder cancer.
    Gourd E
    Lancet Oncol; 2018 Dec; 19(12):e669. PubMed ID: 30509883
    [No Abstract]   [Full Text] [Related]  

  • 22. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
    [No Abstract]   [Full Text] [Related]  

  • 23. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pertuzumab: development beyond breast cancer.
    Barthélémy P; Leblanc J; Goldbarg V; Wendling F; Kurtz JE
    Anticancer Res; 2014 Apr; 34(4):1483-91. PubMed ID: 24692675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pembrolizumab as second-line treatment for urothelial cancer.
    Mitchell F
    Lancet Oncol; 2017 Apr; 18(4):e197. PubMed ID: 28238595
    [No Abstract]   [Full Text] [Related]  

  • 26. Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.
    O'Sullivan CC; Swain SM
    Expert Opin Biol Ther; 2013 May; 13(5):779-90. PubMed ID: 23530718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Labetuzumab govitecan in metastatic colorectal cancer.
    Das M
    Lancet Oncol; 2017 Oct; 18(10):e563. PubMed ID: 28844817
    [No Abstract]   [Full Text] [Related]  

  • 28. Avastin saga reveals debate over clinical trial endpoints.
    Sharma SP
    J Natl Cancer Inst; 2012 Jun; 104(11):800-1. PubMed ID: 22673590
    [No Abstract]   [Full Text] [Related]  

  • 29. Pembrolizumab in advanced head and neck cancer.
    Brower V
    Lancet Oncol; 2017 May; 18(5):e248. PubMed ID: 28366274
    [No Abstract]   [Full Text] [Related]  

  • 30. Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients.
    Cortés J; Ciruelos E; Pérez-García J; Albanell J; García-Estévez L; Ruiz-Borrego M; Espinosa R; Gallegos I; González S; Álvarez I; Llombart A
    Cancer Treat Rev; 2020 Feb; 83():101944. PubMed ID: 31830538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pertuzumab. Promising for some women with metastatic breast cancer, but more assessment needed.
    Prescrire Int; 2014 Apr; 23(148):95. PubMed ID: 24860893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
    Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
    Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual HER2 Blockade Helps Prevent Breast Cancer Return.
    Cancer Discov; 2017 Aug; 7(8):790. PubMed ID: 28588061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moving trastuzumab emtansine (T-DM1) to the early setting of breast cancer treatment.
    Arecco L; Blondeaux E; Damassi A; Fregatti P; Lambertini M
    Ann Palliat Med; 2020 Mar; 9(2):512-516. PubMed ID: 32233615
    [No Abstract]   [Full Text] [Related]  

  • 36. Pertuzumab for the treatment of breast cancer: a safety review.
    Gao J; Swain SM
    Expert Opin Drug Saf; 2016 Jun; 15(6):853-63. PubMed ID: 26982349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 39. [HER2-positive breast cancer: standard and double targeted therapy].
    Semiglazov VF; Bozhok AA; Semiglazova TIu; Vasil'ev AG; Manikhas AG; Semiglazov VV; Bessonov AA; Nikolaev KS
    Vopr Onkol; 2013; 59(3):341-6. PubMed ID: 23909035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
    Megerdichian C; Olimpiadi Y; Hurvitz SA
    Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.